Articles tagged with Vaccine Development
Researchers are developing genetically altered malaria parasites to stimulate immunity against the disease. The goal is to boost the immune system in a similar way to how the altered polio bacteria triggers immunity against polio.
A new study estimates that dengue fever costs over $13 million annually, equivalent to 940,000 lost workdays of output. A potential vaccine could offset 87% of treatment costs, reducing the economic burden on governments and households.
The Yale project aims to create a predictive model system for vaccine testing, addressing the need to predict vaccine safety and effectiveness. The team will study a novel solution using mice engineered with human immune systems, generated with technology developed in Switzerland.
A study found that routine immunisation of infants with the Haemophilus influenzae type b (Hib) vaccine significantly reduced meningitis incidence rates in The Gambia. The researchers hope their findings will encourage other developing countries to adopt Hib vaccination programmes, helping achieve the United Nations' goal of decreasing...
The project aims to formulate a vaccine with a safe, low-cost additive derived from weakened Salmonella bacteria, which can enhance the immune response. A single-dose oral vaccine is also being developed, making it more accessible and practical for use in developing countries.
Researchers have developed a new vaccine that is 100 percent effective in protecting monkeys from infection with deadly viruses Ebola and Marburg. The vaccine targets dendritic cells, which are the same cells attacked by these viruses.
Dr. Albert Z. Kapikian receives the Sabin Gold Medal for developing the first licensed rotavirus vaccine, saving millions of lives worldwide. His pioneering work in electron microscopy and virus characterization has been widely recognized by NIAID Director Anthony Fauci and H.R. Shepherd.
The US vaccine system is fragile and needs significant improvements, the authors report. Despite record low levels of vaccine-preventable diseases and high immunization rates among children, supply chain issues, cost concerns, and safety threats threaten to derail progress.
NIAID has awarded $27 million to institutions and companies to develop medical countermeasures against Category A bioterror agents, including botulinum toxin and Ebola. The awards will support the development of new treatments and therapies using promising scientific discoveries.
Aeras and UCLA announce a license deal for rBCG30, a live recombinant vaccine technology developed at UCLA's David Geffen School of Medicine. The vaccine has shown promising results in initial clinical studies and holds potential to reduce TB disease burden globally.
Researchers at Yale University have identified a molecule that detects parasitic infections in humans, shedding light on how the body recognizes parasites. The discovery of Toxoplasma profilin and TLR11 provides crucial information for developing novel strategies to combat parasitic infections.
A four-year study published in the New England Journal of Medicine confirms RSV as a substantial burden of disease in adults, similar to influenza A. The study calls for the development of an RSV vaccine for elderly and high-risk adults.
Using informatics and computer modelling, researchers can speed up vaccine development by identifying common patterns in 'foreign' protein sequences. This approach has the potential to significantly reduce the number of proteins that need to be experimentally tested.
A new influenza vaccine developed using insect cells can produce a strong immune response in humans and may be scaled up for commercial manufacture. This rapid method uses a purified concentration of hemagglutinin to elicit an immune response against specific flu strains.
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting applications for Clinical Trials Units to lead in the development and evaluation of treatments, prevention strategies, and vaccines for HIV/AIDS. The selected units will focus on interventions that can be employed in resource-limited settings.
Researchers at UCI create a new method to rapidly discover antigens for vaccines, enabling the expression of hundreds of proteins in just one week. This technique addresses the bottleneck in processing large amounts of data from genome sequences, allowing for faster vaccine development and improved safety.
The Global HIV/AIDS Vaccine Enterprise has launched a scientific strategic plan to address major roadblocks in HIV vaccine development and proposes an innovative collaborative model for researchers worldwide. The plan aims to harness new opportunities, including an expanded pipeline of HIV vaccine candidates and improved animal models.
A vaccine against cervical cancer has been developed by Dutch researcher Laura Bungener. The vaccine induces an immune response to proteins from human papillomavirus (HPV), rendering it harmless and preventing the growth of tumors. Laboratory animals with existing tumors could also be treated with this vaccination.
The NIAID human clinical vaccine trial tests an experimental vaccine composed of a small circular piece of DNA encoding the viral spike protein. The trial aims to assess the vaccine's safety and immune-stimulating effects in people, with results expected to inform future vaccine development.
The Imperial College London team, led by Dr. Danny Altmann, is developing new vaccines against anthrax and other bio-weapons using state-of-the-art technologies. The research will also contribute to a better understanding of emerging infectious diseases and the development of effective diagnostics and treatments.
A recent UK study published in The Lancet has found no association between the MMR vaccine and the development of autism or pervasive developmental disorders. Researchers analyzed data from over 1,300 cases and 4,469 controls, concluding that vaccination did not increase the risk of these conditions.
Researchers at UCI are working on a vaccine against melioidosis, caused by B. pseudomallei, a bacterium that thrives in water and can cause severe pneumonia and septic shock. The development of a safe and effective vaccine is crucial to blunt bioterrorism threats.
A phase 1 vaccine trial has demonstrated that a group A streptococcal vaccine appears safe and well-tolerated, inducing immune responses capable of conferring protection against multiple strains. The study's findings suggest that a specific dose and schedule may be effective in preventing group A streptococcal infections.
A novel protein vaccine candidate has demonstrated full protection against a lethal aerosol challenge with ricin toxin in mice, offering a promising solution to bioterrorism threats. The vaccine, RTA 1-33/44-198, was designed using molecular modeling and protein engineering techniques.
A new breed of vaccine-producing plants is being developed to combat global health issues, including cholera and diarrhea. The innovative technology uses minimal processing to yield heat-stable vaccines for oral delivery.
A new triple-vaccine strategy has been shown to stimulate a strong HIV-specific immune response in monkeys, demonstrating its potential as an improved method of protection against the virus. The approach uses a series of three vaccines that build on each other to generate a stronger immune response than might otherwise be possible.
Researchers have developed an intranasal SARS vaccine that protects African green monkeys from infection with a single dose, delivering the vaccine directly into the respiratory tract. The vaccine targets the SARS spike protein and induces neutralizing antibodies against the virus.
Researchers found thimerosal exposure in mice led to autism-like behaviors, including abnormal responses to environments and brain abnormalities. The study suggests a potential connection between genetic susceptibility and environmental triggers for autism, highlighting the need for further research and intervention strategies.
Researchers at Saint Louis University have demonstrated that the smallpox vaccine candidate LC16m8 protects mice from a virus related to smallpox when delivered via aerosol. The study aims to develop a safer smallpox vaccine for bioterrorism threats.
Researchers have developed a new vaccine strategy using live, crippled Salmonella bacteria that stimulate immunity to multiple pathogens. The vaccine protected mice 100% against lethal doses of both S. typhimurium and Listeria monocytogenes.
The NIAID-licensed rotavirus vaccine has been developed to combat severe diarrhea in infants and young children worldwide. The vaccine has shown promise in reducing the number of deaths caused by rotavirus infections, particularly in developing countries where access to effective treatments is limited.
A new investigational anthrax vaccine is being tested in a phase II human study at Saint Louis University. The vaccine aims to provide better protection, an improved safety profile and a simpler dosing schedule.
Researchers develop two SARS vaccine candidates that effectively protect mice from infection, utilizing different technologies to stimulate the immune system. The vaccines target the S protein, a key component of the coronavirus responsible for initiating infection.
The collaboration aims to improve the BCG vaccine, which offers protection against serious forms of TB in childhood but loses efficacy over time. A new vaccine is crucial to combating the disease that kills over two million people globally per year.
Researchers have successfully tested a new plague vaccine in a real-world mouse model, showing promising results. The vaccine was tested in a natural transmission setting, where infected fleas fed on vaccinated mice, and showed protection against the disease.
A consortium has launched a programme to develop a TB vaccine, with the Max Planck Institute for Infection Biology developing a highly promising candidate. The vaccine aims to improve upon the existing BCG vaccine, which lacks effectiveness against pneumotuberculosis.
A new TB vaccine, rBCG30, is being tested in a human clinical trial to assess its safety and immune response. The vaccine, developed by Dr. Marcus Horwitz and his team at UCLA, has shown promise in preclinical trials and could potentially reduce the TB disease burden worldwide.
Researchers found that even delayed responses to smallpox cases could still contain the outbreak through targeted vaccination and isolation. Surveillance and containment were more effective than mass vaccination in controlling the spread of smallpox.
Researchers are testing a new flu vaccine that delivers the vaccine in the nose to observe differences in immune system reactions. The study aims to improve immunity in the respiratory tract for all pathogens, with implications for biodefense.
The Gates Foundation has committed $82.9 million to develop new tuberculosis vaccines, with the goal of creating a more effective vaccine within 10 years. The grant will support research in three major areas: vaccine trials, improved animal models, and next-generation vaccines.
The National Vaccine Advisory Committee recommends strengthening routine vaccine supplies by increasing funds for stockpiles, supporting regulatory agencies, and improving communication. The committee also highlights the need for increased investment in vaccine manufacturing facilities and development of new vaccines to sustain supply.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
St. Jude experts highlight US vaccine production inadequacies and antiviral drug scarcity in responding to an outbreak, emphasizing the need for new technologies, international cooperation, and rapid testing.
The IU School of Medicine and Merck have partnered to establish a vaccination training program in Kenya. The program aims to enhance immunization infrastructure and reduce infant morbidity and mortality due to preventable diseases.
Researchers at Georgia Tech have made significant progress in developing hollow and solid microneedles that can deliver proteins, nanoparticles, and large molecules through the skin with minimal pain. The technology has potential applications in treating various diseases, including diabetes.
A Phase II clinical study of TP10 found that the complement inhibitor significantly reduced heart attacks and death in male patients undergoing open heart surgery. The study showed a significant decrease in composite endpoints for death, myocardial infarction, and prolonged intubation in males treated with TP10.
Researchers developed vaccines based on human and chimpanzee adenoviruses to protect newborns against viral diseases. These oral vaccines have the potential to be effective even with waning maternal antibodies, offering a crucial solution for infants in developing countries.
A South African clinical trial showed a significant reduction in pneumococcal disease incidence with the conjugate vaccine, resulting in a 5% decrease among all children and a 6% decrease among HIV-infected children. The study demonstrates the vaccine's effectiveness in preventing invasive pneumococcal disease and saving lives.
Four research organizations will receive funding to develop promising HIV vaccine candidates using DNA vaccines, virus vector vaccines, subunit vaccines, and virus-like particle vaccines. Researchers aim to induce strong cellular and antibody immune responses in animal models.
The NIH has awarded $85 million to five cooperative centers for translational research on human immunology and biodefense. Researchers will develop new ways to analyze immune cells and use imaging technologies to study vaccine responses, aiming to strengthen the immune system against diseases.
A malaria vaccine trial has begun in Mali with support from NIAID, aiming to prevent the deadliest form of malaria. The FMP-1 vaccine, developed by WRAIR and GSK Biologicals, will be tested on 40 adults for one year to assess its safety and efficacy.
The Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB) will develop new vaccines and diagnostics for orthopoxviruses, Bacillus anthracis, and Y. pestis. The consortium aims to address difficult problems in emerging infections with unprecedented speed.
The Wyeth Pharmaceuticals team is being recognized for their role in developing the first combined pneumococcal vaccine for infants, Prevnar. The vaccine has dramatically advanced the health and well-being of children worldwide by preventing serious diseases such as meningitis, bacteremia, and pneumonia.
The US Army has awarded a $1 million grant to Virginia Tech researcher Thomas J. Inzana to develop a vaccine and diagnostic test for tularemia, also known as 'rabbit fever'. The goal is to create an effective vaccine that can stimulate the production of proteins that stimulate T-cells of the cellular immune system.
The trial, led by Saint Louis University, is a phase I trial investigating the safety and immune response of EP HIV-1090 vaccine candidate. Participants will receive the vaccine or placebo over 18 months, with observations to assess its potential effectiveness against HIV.
The St. Jude team successfully developed a custom-made vaccine against the H5N1 flu virus in just four weeks, thanks to a modified technique called reverse genetics. The vaccine was created by mixing genes from H5N1 with those from a common flu virus, making it safe for human use.
The Johns Hopkins Bloomberg School of Public Health has been awarded $30 million to develop and introduce a pneumococcal vaccine for children in the world's poorest countries. The Pneumococcal Accelerated Development and Introduction Plan (ADIP) team will work with international partners to address research, supply, and financing issue...
The Lancet discusses the conflict between scientific openness and global security concerns, highlighting the need for defensive biological research to prevent the spread of knowledge and dangerous materials. Pneumococcal vaccines are also reviewed, showing varying effectiveness in developed countries.
AVANT Immunotherapeutics awarded subcontract to develop oral combination vaccine against anthrax and plague using proprietary technologies. The vaccine aims to offer rapid, effective protection from multiple biological agents with a single dose, eliminating the need for protracted dosing regimens.
Researchers found that patients infected with one strain of HIV can develop superinfection with another strain, compromising treatment. Genetic analysis confirmed the presence of a second type of HIV in the patient's blood, indicating that superinfection is possible and poses unique challenges for vaccine development.